A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

Gastrointestinal Stromal Tumor

Recruiting

1

Start Date 12/01/2021

Age of Trial (yrs) 3.5

Gleevec-resistant

HSP90 inhibitor

Block KIT

Specifically GIST and only GIST

10058060

Taiho Pharmaceutical Co., Ltd.

Drug Information Center +81-3-3294-4527 n-arimura@taiho.co.jp

Randomized

Oral

Brief Summary:
This study consists of Dose escalation part and Expansion part. In Dose Escalation Part, the maximum tolerated dose of combination of pimitespib and imatinib in patients with gastrointestinal stromal tumors (GIST) who are judged to be refractory to imatinib, estimate the recommended dose, evaluate safety and pharmacokinetics, and observe the antitumor effect. Expansion part consists of 3 arms. In Arm A, the efficacy and safety will be evaluated, which of the combination of pimitespib and imatinib in patients with GIST who have failed imatinib at doses below the MTD determined in Dose Escalation Part. In Arm B, the efficacy and safety of pimitespib monotherapy will be evaluated and the therapeutic effect of imatinib administration after pimitespib will be evaluated in an exploratory manner. In Arm C, the efficacy and safety of sunitinib monotherapy will be evaluated as reference data.
Criteria

Inclusion Criteria:

Provided written informed consent
Histologically confirmed GIST
Has radiographic progression based on RECIST 1.1 during or within 6 months of the last imatinib administration at enrollment. If surgery/radiotherapy has been performed, radiographic progression based on RECIST 1.1 with imatinib must have been observed after the last surgery /radiotherapy
Has at least one measurable lesion based on the RECIST version 1.1, except lymph nodes (not dependent on size), which should be chosen as nontarget lesions;
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

Exclusion Criteria:

Corrected visual acuity < 0.5 (using the International Visual Acuity Measurement Standard) for both eyes
Received treatment with any other line of therapy besides imatinib for advanced GIST
History of total gastrectomy and/or whole resection of the small intestine
A serious illness or medical condition
Previous or concurrent cancer that is distinct in primary disease or histology from cancer that is being evaluated in this study. However, any previous cancer curatively treated > 5 years before the enrollment can be eligible
Pregnancy or lactation (including lactation interruption)